OS Therapies (NYSEAMERICAN:OSTX) Downgraded to Strong Sell Rating by Zacks Research

OS Therapies (NYSEAMERICAN:OSTX) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday,Zacks.com reports.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a report on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $18.50.

OS Therapies Stock Performance

OS Therapies stock opened at $1.70 on Wednesday. OS Therapies has a fifty-two week low of $1.15 and a fifty-two week high of $2.57. The firm has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.55. The company has a market capitalization of $67.20 million, a PE ratio of -1.72 and a beta of -1.34.

OS Therapies (NYSEAMERICAN:OSTX) last posted its earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter. As a group, equities research analysts forecast that OS Therapies will post -0.54 earnings per share for the current year.

Institutional Trading of OS Therapies

Several institutional investors have recently added to or reduced their stakes in the stock. CM Management LLC increased its holdings in OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC boosted its position in OS Therapies by 31.1% in the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after buying an additional 58,350 shares during the period. Millennium Management LLC purchased a new position in OS Therapies in the 3rd quarter valued at approximately $183,000. Two Sigma Investments LP purchased a new position in OS Therapies in the 3rd quarter valued at approximately $169,000. Finally, Virtu Financial LLC boosted its position in OS Therapies by 252.0% in the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after buying an additional 54,269 shares during the period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.